Your Article Summary
See Latest ArticlesEarly versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: A long-term, retrospective analysis
European Journal of Neurology, 07/02/09
Nissinen H et al. – Data suggest that early vs delayed addition of entacapone to levodopa/ dopa-decarboxylase inhibitor (DDCI) in Parkinson's disease (PD) pts with wearing-off provides a modest clinical benefit over levodopa/DDCI that is maintained for up to 5 yrs.
Methods- Data analysis from 3 clinical trials in PD pts with wearing-off to determine whether early enhancement of levodopa therapy with entacapone can lead to better long-term outcomes than delayed entacapone treatment
- Post-hoc analysis of pooled data from 3 randomized, double-blind, placebo-controlled studies and their long-term, open-label extension phases
- In all 3 studies, DDCI pts first randomized to entacapone ('early-start' group) or placebo ('delayed-start' group) for initial 6-mo double-blind phase, then open-label levodopa/DDCI and entacapone treatment for up to 5 yrs for all pts
- Total of 488 PD pts with wearing-off analyzed
- Statistically significant benefit of early initiation of levodopa/DDCI and entacapone
- Improvement in Unified Parkinson's Disease Rating Scale Part III (motor) score of ?1.66 points vs delayed-start treatment group
- Levodopa/DDCI and entacapone therapy well tolerated
- No excess of dyskinesia in early-start group
Related Articles
Widely Used Cholesterol-lowering Drug May Prevent Progression Of Parkinsons Disease
ScienceDaily, 11/10/09
Relevance Score: 70%
Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia
Brain, 10/30/09
Relevance Score: 70%
Effects of optimism/pessimism and locus of control on disability and quality of life in Parkinson's disease
Parkinsonism & Related Disorders, 10/29/09
Relevance Score: 69%
Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS
Parkinsonism & Related Disorders, 10/29/09
Relevance Score: 69%
Condition Raises Parkinsons Risk 5-Fold
Ivanhoe, 10/27/09
Relevance Score: 69%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/10/09
Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/10/09
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09